Phase 3 Study of Nemtabrutinib Plus Venetoclax vs VR in 2L+ R/R CLL/SLL

• Research type

  Research Study

• Full title

  A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib (MK-1026) Plus Venetoclax Versus Venetoclax Plus Rituximab in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Following at Least 1 Prior Therapy (BELLWAVE-010)

• IRAS ID

  1006862

• Contact name

  - -

• Contact email

  N/A

• Sponsor organisation

  Merck Sharp & Dohme LLC

• Research summary

  Please refer to document ‘39. Lay Summary_27-Mar-2023_Clean’ within the system for full approved lay summary.

• REC name

  London - Harrow Research Ethics Committee

• REC reference

  23/LO/0078

• Date of REC Opinion

  21 Sep 2023

• REC opinion

  Further Information Favourable Opinion